Charting the course of clinical research: From an inspired past to a promising future

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 190-192

  Armstrong, Paul W ^a   Kaul, Padma ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; FINANCIAL MANAGEMENT; FUTUROLOGY; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; METHODOLOGY; PRIORITY JOURNAL; RESEARCH ETHICS; ST SEGMENT ELEVATION;

BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; INDUSTRY; INFORMED CONSENT; INTERPROFESSIONAL RELATIONS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 4143148585     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.054     Document Type: Editorial

References (13)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-402
2. Armstrong P.W., Collen D. Fibrinolysis for acute myocardial infarction current status and new horizons for pharmacological reperfusion: part I. Circulation. 103:2001;2862-2866
3. Tavazzi L., Maggioni A.P., Tognoni G. Participation versus education the GISSI story and beyond. Am Heart J. 148:2004;223-229
4. Fontaine N, Rosengren B. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities. 2001;L121:34-44
5. Bassand J.-P., Martin J., Ryden L., et al. The need for resources for clinical research the European Society of Cardiology calls for European, international collaboration. Lancet. 360:2002;1866-1869
6. Eisenstein EL, Lemons BW, Tardiff BE, et al. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J (in press)
7. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
8. Topol E.J., Califf R.M., Van de Werf F., et al. Perspectives on large scale cardiovascular clinical trials for the new millennium. Circulation. 95:1997;1072-1082
9. Topol E.J., Armstrong P.W., Van de Werf F., et al. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol. 19:1992;1123-1128
10. VIGOUR website. Available at: http://www.vigour.ualberta.ca/
11. HERO 2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction the HERO-2 randomized trial. Lancet. 358:2001;1855-1863
12. Gupta M., Chang W.-C., Van de Werf F., et al. International differ-ences in in-hospital revascularization and outcomes following acute myocardial infarction a multilevel analysis of patients in ASSENT 2. Eur Heart J. 24:2003;1640-1650
13. Kramer J.M., Newby K., Chang W.-C., et al. International variation in the use of evidence-based medicines for acute coronary syndromes. Eur Heart J. 24:2003;2133-2141